CSIMarket
 
Sight Sciences Inc   (SGHT)
Other Ticker:  
 
 
Price: $4.1100 $0.09 2.239%
Day's High: $4.215 Week Perf: -8.05 %
Day's Low: $ 4.01 30 Day Perf: -3.07 %
Volume (M): 105 52 Wk High: $ 11.20
Volume (M$): $ 432 52 Wk Avg: $6.22
Open: $4.02 52 Wk Low: $1.04



 Market Capitalization (Millions $) 200
 Shares Outstanding (Millions) 49
 Employees -
 Revenues (TTM) (Millions $) 82
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 1

Sight Sciences Inc
Sight Sciences Inc. is a medical technology company focused on designing and developing non-surgical treatments for patients with vision-threatening eye diseases. The company's primary aim is to improve surgical outcomes and enhance patient quality of life through innovative and minimally invasive solutions. Its products include the OMNI Surgical System, a comprehensive platform for the treatment of glaucoma, as well as the TearCare System, which provides a novel approach to treating evaporative dry eye. Sight Sciences Inc. is known for its commitment to advancing ophthalmic care and addressing unmet needs in the field.


   Company Address: 4040 Campbell Ave Menlo Park 94025 CA
   Company Phone Number: 266-1144   Stock Exchange / Ticker: NASDAQ SGHT
   SGHT is expected to report next financial results on March 07, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Sight Sciences Launches Game-Changing ERGO-Series of OMNI Surgical System, Revamping Glaucoma Surgery at ESCRS Winter Meeting

Published Wed, Feb 14 2024 9:05 PM UTC

Sight Sciences Revolutionizes Glaucoma Surgery with European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter MeetingMENLO PARK, Calif., Feb. 14, 2024 - Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company, has announced the European launch of the Ergo-Series of the OMNI Surgical System. This groundbreaking technology is designed...

Stock Market Announcement

Company X's Strategic Refinancing Points Towards Financial Stability and Growth.

Published Tue, Jan 23 2024 9:05 PM UTC

Refinancing Replaces Prior Senior Credit Facility: A Step Towards Financial Stability
In the ever-evolving landscape of finance, companies often need to adapt and find innovative solutions to manage their debt and maintain financial stability. This was precisely the case for Company X, a prominent player in the industry. A recent press release announced that the company ...

Clinical Study

TearCare: A New Vision for Dry Eye Relief - Revolutionary Eyelid Interventions Prove Successful in Clinical Trial

Published Mon, Dec 18 2023 9:05 PM UTC

TearCare Eyelid Procedures Show Promising Results in Treating Dry Eye Disease: SAHARA Clinical Trial Reveals Significant Improvements
In a recent press release, Sight Sciences, a leading medical technology company, announced the successful publication of the SAHARA randomized controlled clinical trial. The trial compared the effectiveness of TearCare, a technology enabli...

Clinical Study

Sustained IOP Reductions and Medication Reductions Demonstrated in Three-Year GEMINI 2 Trial - OMNI Surgical System Proves its Long-term Safety and Efficacy

Published Fri, Dec 8 2023 1:05 PM UTC


Sight Sciences, a leading medical device company, has recently made an exciting announcement regarding the acceptance for publication of GEMINI 2, a three-year, prospective, multicenter trial evaluating the OMNI Surgical System technology. The results of this trial have demonstrated sustained and significant reductions in intraocular pressure (IOP) and medication usage,...

Sight Sciences Inc

Sight Sciences Inc's Future Shines Bright as Investors Thrive on Promising Results

Investors Optimistic About Sight Sciences Inc's Future Performance
Sight Sciences Inc, a leading medical equipment and supplies company, has shown promising results in the third quarter of 2023, with a decrease in loss per share and an improvement in earnings per share compared to the previous year. While the revenue increased slightly by 3.507% to $19.33 million from $18.68 million in the same reporting period a year ago, it fell sequentially by -16.275% from $23.09 million.
Despite the revenue gain lagging behind contemporaries in the Medical Equipment & Supplies sector, Sight Sciences Inc experienced a 4.03% improvement in revenue compared to the third quarter of 2022. These results indicate a positive trajectory for the company's financial performance.






 

Sight Sciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com